Chinese Upstart Ascletis Bags $100 Million in Series B Financing

Chinese biotech company Ascletis, which focuses on treatments of liver disease, scored $100 million in a Series B financing round. The company said it intends to use the proceeds to advance its pipeline as well as its sales force.

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Life Science Leaders Celebrate Global Partnerships During WuXi Global Forum 2018

More than 2,000 life science industry insiders around the globe participated in the WuXi Global Forum on Jan. 9, 2018 during the annual J.P....

WuXi Global Forum 2018